Trial Profile
A Phase 1b/2, Multicenter, Open-Label Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors Nivolumab or Pembrolizumab in Adult Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 18 Oct 2023
Price :
$35
*
At a glance
- Drugs Adegramotide/nelatimotide (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Cervical cancer; Colorectal cancer; Fallopian tube cancer; Gastric cancer; Head and neck cancer; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Peritoneal cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer; Urogenital cancer; Wilms' tumour
- Focus Adverse reactions; Therapeutic Use
- Acronyms WIZARD101CI
- Sponsors Boston Biomedical; Sumitomo Pharma America; Sumitomo Pharma Oncology
- 06 Dec 2022 Status changed from active, no longer recruiting to completed.
- 18 Nov 2022 Planned End Date changed from 1 Feb 2024 to 19 Nov 2022.
- 13 Apr 2022 Results (at data cut-off: 30 March 2021; n=13) presented at the 113th Annual Meeting of the American Association for Cancer Research.